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Psychedelic new psychoactive substances (NPS), compounds exerting their main 
pharmacological effects through the activation of the serotonin 2A receptor (5-HT2AR), 
continuously comprise a substantial portion of the reported NPS. However, these substances 
and their exact mechanism of action, differentiating them from non-psychedelic 5-HT2AR 
agonists, require further characterization. One potentially relevant phenomenon is the 
occurrence of biased agonism, in which (a) certain signaling pathway(s) is preferentially 
activated over the other(s). To this end, a new bioassay was developed, monitoring the 
recruitment of an engineered miniGαq protein to the activated 5-HT2AR. The setup was designed 
to be analogous to that of a previously developed bioassay monitoring β-arrestin 2 recruitment 
through the NanoBiT system, enabling estimation of the potential preference of a substance to 
trigger recruitment of one protein over the other. This approach yielded several statistically 
significantly biased agonists within the group of phenylalkylamine psychedelics, more 
specifically the N-benzyl substituted 25H analogues 25H-NBF, 25H-NBMD, 25H-NBOH and 
25H-NBOMe. All four compounds show a statistically significant preference towards the 
recruitment of β-arrestin 2 over miniGαq, as compared to the reference psychedelic substance 
LSD. We identified markedly different responses for Bromo-DragonFLY in the two bioassays, 
suggesting biased agonism, though the calculated bias factor equalled out to approximately 0. 
This demonstrates that the accurate assessment of biased agonism requires both the 
consideration of the observed trends in addition to the numerical value of the bias factor. A 
second panel of structural (I-substituted) analogues of the former group of phenylalkylamines 
showed a similar trend in the ranking order of the bias factors, resulting in one additional 
compound (25I-NBF) being statistically significantly biased.  
Keywords: psychedelics, hallucinogens, biased agonism, G protein-coupled receptor, 
serotonin 2A receptor 
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1. Introduction  
The serotonin (5-HT) 2A receptor (5-HT2AR) is a G protein-coupled receptor (GPCR) with 
roles in a wide variety of processes, such as mood, learning, memory, sleep-wake cycles and 
appetite. The 5-HT2AR receptor is expressed mainly in platelets, the gastro-intestinal tract and 
the central nervous system, and is involved in several disorders with rather complex etiologies, 
e.g. depression, eating disorders and schizophrenia.[1, 2] In order to fulfill this multitude of 
functions, the 5-HT2AR is linked to a variety of downstream signaling pathways via the 
recruitment of a number of cytosolic proteins, amongst which the canonical Gαq protein and 
the scaffolding protein β-arrestin 2 (βarr2).[1, 3-6] 
Besides exerting physiological and pathological functions, the 5-HT2AR also plays an important 
role in the mechanism of action of serotonergic psychedelics, substances defined to exert their 
main pharmacological effects through this receptor.[3] This group of substances can be divided 
into three structural subclasses: ergolines (with lysergic acid diethylamide (LSD) as 
prototypical representative), tryptamines (e.g. DMT) and psychedelic phenylalkylamines (such 
as the naturally occurring mescaline).[7] Apart from the more ‘conventional’ psychedelics, over 
the past years a large variety of psychedelic NPS (new psychoactive substances) has been 
reported: compounds mimicking the effects of e.g. LSD, while being structurally distinct. 
Psychedelic NPS have been a consistently abundant class within the group of newly detected 
NPS reported to the United Nations Office on Drugs and Crime (UNODC).[8-11] 
The effects sought for by users of psychedelic substances include altered states of 
consciousness, empathic feelings and mystical experiences. However, their use may also result 
in severe adverse reactions, amongst which agitation, headaches, convulsions, renal failure, 
rhabdomyolysis and even death, specifically with the more recent group of NPS.[4, 11, 12] 
Besides the effects that make these substances attractive to illicit drug users, serotonergic 
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psychedelics are increasingly recognized for having therapeutically interesting properties. 
Clinical trials with mainly LSD and psilocybin, in the context of treating addictions and 
ameliorating distress concerning death, invigorate this hypothesis, and psychedelic substances 
have been suggested as therapeutically useful in other (psychiatric) conditions as well.[13-15] 
Even though the group of psychedelic substances is highly relevant from both a therapeutic and 
a substance abuse perspective, the precise mechanism of action that distinguishes them from 
non-psychedelic 5-HT2AR agonists remains elusive.[5, 6, 15] Proposed mechanisms include the 
activation of distinct signaling events, the occurrence of biased agonism, the binding of these 
substances to other GPCRs, and the involvement of GPCR dimerization.[4-6, 16] Biased 
agonism or functional selectivity can be defined as the differential activation of signaling 
pathways by distinct ligands at the same GPCR. When pathways can be linked to respective 
effects, this can enable the development of pharmaceuticals with more beneficial therapeutic 
properties.[17-19] The assessment of this phenomenon is greatly hampered by the difficulty to 
comparatively interpret the results obtained with distinct assays. More specifically, applied 
assays can differ in terms of systems used for measuring (readout method, saturability of the 
system, potential temporal bias, distinct expression levels and the use of native versus modified 
receptor or transducer constructs), and in cell context (with possibly different expression levels, 
and co-expression of GPCR isoforms and off-target proteins).[20, 21] 
This study is the first to use two distinct yet highly analogous in vitro bioassays to 
systematically investigate the potentially biased agonism of a set of structurally diverse 
psychedelic NPS, representing both the tryptamine and phenylalkylamine subgroup. To this 
end, the recruitment of either βarr2 or an engineered miniGαq protein to the activated 5-HT2AR 
was monitored.[22] This latter protein consists of the thermodynamically stabilized Ras domain 
of the Gαq subunit.[23-25] The recruitment of both proteins can be monitored via a luminescent 
readout, obtained through the NanoBiT® system, in HEK 293T cells transiently transfected with 
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the concerned constructs. This simultaneous monitoring in highly similar systems, representing 
signaling events upstream of the signaling cascade, allowed for the assessment of biased 
agonism of these compounds, via the intrinsic relative activity approach.[18, 19, 26] It is, to the 
best of our knowledge, the first time a βarr2 recruitment assay is used for the assessment of 
biased agonism in a large set of psychedelic substances at the 5-HT2AR on a molecular level.  
2. Materials and methods  
2.1 Chemicals and reagents  
Dulbecco’s Modified Eagle Medium (DMEM, supplemented with GlutaMAX®), Hank’s 
Balanced Salt Solution (HBSS), Phusion High Fidelity PCR Master Mix, restriction enzyme 
EcoRI, Amphotericin B (250 µg/mL) and penicillin/streptomycin (10 000 IU/mL and 10 000 
µg/mL) were procured from Thermo Fisher Scientific (Pittsburg, PA, USA). The plasmid 
containing miniGαq was a kind gift of Dr. A. Chevigné (Luxembourg Institute of Health). 
Transfection reagent FuGENE®, thermosensitive alkaline phosphatase (TSAP) and the Nano-
Glo Live Cell reagent and LCS Dilution buffer were from Promega (Madison, WI, USA). The 
analytical standard of LSD (lysergic acid diethylamide), Fetal Bovine Serum (FBS) and poly-
D-lysine hydrobromide were purchased from Sigma-Aldrich (Overijse, Belgium). The Human 
Embryonic Kidney (HEK) 293T cells (passage 20) were kindly gifted by Prof. O. De Wever 
(Ghent University Hospital, Belgium). The analytical standards of Mescaline HCl (3,4,5-
trimethoxy-benzeneethanamine); 2C-H HCl (2,5-dimethoxy-benzeneethanamine); DOH HCl 
(DL-2,5-dimethoxyamphetamine); 25H-NBOH HCl (2-[[[2-(2,5-
dimethoxyphenyl)ethyl]amino]methyl]-phenol); 25H-NBOMe HCl (2-(2,5-dimethoxyphenyl)-
N-(2-methoxybenzyl)ethanamine); 25H-NBF HCl (2-(2,5-dimethoxyphenyl)-N-(2-
fluorobenzyl)ethanamine); 25H-NBMD HCl (N-(benzo[d][1,3]dioxol-4-ylmethyl)-2-(2,5-
dimethoxyphenyl)ethanamine); N-Me-2C-H HCl (2,5-Dimethoxy-N-methylphenethylamine); 
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25I-NBOH HCl (2-(((4-iodo-2,5-dimethoxyphenethyl)amino)methyl)phenol); 2C-B-FLY HCl 
(8-bromo-2,3,6,7-tetrahydro-benzo[1,2-b:4,5-b']difuran-4-ethanamine) and DOI HCl (DL-2,5-
dimethoxy-4-iodoamphetamine) were bought from Chiron AS (Trondheim, Norway). DIPT 
HCl (N,N-Diisopropyltryptamine), DMT hemifumarate (N,N-Dimethyltryptamine), DPT HCl 
(N,N-Dipropyltryptamine), and Bromo-DragonFLY HCl (8-bromo-α-methyl-benzo[1,2-b:4,5-
b']difuran-4-ethanamine) and R-Bromo-DragonFLY HCl were kindly gifted by Chiron AS. The 
analytical standards of 25I-NBMD HCl (N-(benzo[d][1,3]dioxol-4-ylmethyl)-2-(4-iodo-2,5-
dimethoxyphenyl)ethanamine) and 25I-NBF HCl (N-(2-fluorobenzyl)-2-(4-iodo-2,5-
dimethoxyphenyl)ethanamine) were purchased from Cayman Chemical Company (Ann Arbor, 
MI, USA). The standards of 2C-I HCl (4-iodo-2,5-dimethoxy-benzeneethanamine) and 25I-
NBOMe HCl (4-iodo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine) 
were kindly gifted by Prof. K. Maudens, who procured them from the Australian Government 
National Measurement Institute and Cayman Chemical Company, respectively. The structures 
of all evaluated compounds are given in Figure 1. 
2.2 Cloning of the miniGαq constructs in the NanoBiT system 
Four miniGαq constructs were generated, N- or C-terminally fused to the NanoBiT subunits 
(miniGαq-LgBiT, miniGαq-SmBiT, LgBiT-miniGαq and SmBiT-miniGαq) according to 
standard cloning procedures, as described previously for the receptor constructs (5-HT2AR-
LgBiT and 5-HT2AR-SmBiT).[22] The polymerase chain reaction (PCR) was performed by 
mixing 2.5 µM of each of the forward and reverse primers (for the former two constructs, the 
forward primer was ATCCAAGAATTCACCATGATCGAGAAGCAGC and the reverse 
primer ATCCAAGAATTCCCGACGAGGTTGTACTCTCTCAGG, for the latter two 
ATCCAAGAATTCAATGATCGAGAAGCAGC and 
ATCCAAGAATTCTCAGACGAGGTTGTACTCTCTCAGG, respectively; EcoRI restriction 
sites are underlined) with PCR Mastermix and 100 pg of the template DNA. The three-step 
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PCR consisted of initial denaturation (98°C, 30 s), denaturation (98°C, 10 s), annealing (66.9°C, 
20 s), elongation (72°C, 25 s) and final elongation (72°C, 5 min), of which the three middle 
steps were repeated 32 times. After purification, the reaction product was digested with the 
restriction enzyme EcoRI. Three microgram of each of the respective vectors (NB MCS-1 to -
4) was digested with the same restriction enzyme, purified, and digested with TSAP. The 
digested vectors and inserts were ligated using T4 DNA ligase, the products were heat-shock 
transformed into chemically competent E.coli, and plated onto ampicillin-containing agar 
plates. After growing overnight, colonies containing the aimed construct were selected via PCR, 
and grown in LB broth. The correctness of the constructs was verified via Sanger sequencing.  
2.3 Routine Cell culture  
Human embryonic Kidney Cells (HEK 293T) were routinely maintained in DMEM (with 
GlutaMAX®), supplemented with 10 % heat-inactivated FBS, 100 IU/mL of penicillin, 0.25 
µg/mL amphotericin B and 100 µg/mL streptomycin, in a humidified atmosphere of 37 °C and 
5 % CO2. Cells were used until passage 25.  
2.4 Transient transfection protocol: selection of the optimal combination and use for 
compound screening  
The βarr2 and miniGαq recruitment assays in the NanoBiT
® system were performed via a 
transient transfection protocol, as described before.[22, 27] In brief, routinely cultured HEK 
293T cells were seeded in 6-well plates, at a density of 500 000 cells per well, and incubated 
overnight. Subsequently, each well was transfected with 3.3 µg of DNA, consisting of equal 
quantities of both the receptor and βarr2 or miniGαq constructs, in a 3:1 FuGENE
®:DNA ratio 
according to the manufacturer’s protocol. Twenty-four hours post transfection, the cells were 
reseeded into poly-D-lysine coated 96-well plates at a density of 50 000 cells per well, and 
incubated for another 24 h before the readout took place. First, the cells were washed twice with 
9 
 
HBSS, and 100 µL of HBSS was pipetted into each well. Then, 25 µL of the Nano-Glo Live 
Cell reagent (substrate, diluted 1/20 in Nano-Glo LCS Dilution buffer according to 
manufacturer’s protocol) was added, and the plate was placed in the Tristar2 LB 942 multimode 
microplate reader (Berthold Technologies GmbH & Co, Germany). After equilibration of the 
luminescent signal, the 13.5 x concentrated agonist(s) was (were) added to each well, and the 
signal was monitored for 2 h.  
For the selection of the optimal combination of miniGαq- and 5-HT2AR-constructs in the 
NanoBiT® system, each of the combinations was transfected and tested at a fixed concentration 
of 1 µM LSD. In the experiments performed for characterization of the ligand bias of the 
compounds, all tested compounds were tested at concentrations of (100 µM) – (25 µM) – (10 
µM) – 1 µM – 10–7 M – 10-8 M – 10-9 M – 10-10 M – 10-11 M – (10-12 M), in at least three 
independent experiments, each performed in duplicate. The βarr2 and miniGαq assays were 
performed in parallel, using the same dilutions of the compounds for both assays, and LSD was 
run as a reference agonist on all plates. Appropriate solvent controls were included in all 
experiments.  
2.5 Data processing and statistical analysis  
The time-luminescence profiles obtained during the luminescence analysis were corrected for 
interwell variability and used for the calculation of the area under the curve (AUC), as 
previously described in more detail.[28] After subtraction of the AUC of the corresponding 
solvent control, concentration-response curves were generated via GraphPad Prism software 
(San Diego, CA, USA), using the three-parametric nonlinear regression model. This model 
implies the use of a Hill slope fixed at 1, which is a requirement to be fulfilled for the 
implementation of the ligand bias calculation described below.[18, 26] Data points associated 
with the highest concentration(s) were excluded in case of a reduction of 20 % or more, as 
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compared to the next (less concentrated) dilution. This 20% cut-off point for exclusion was 
defined a priori, based on previous experience with multiple receptor systems, and was applied 
consistently, with as a rationale that (very) high concentrations could potentially lead to cell 
toxicity or solubility issues, and inclusion of these data points could inadvertently skew the 
obtained results.[29] For each separate experiment, the data were normalized for the maximal 
response of the reference agonist LSD, and finally bundled to obtain the total EC50 and Emax 
values for each compound.  
To quantify the tendency of a compound to induce preferential recruitment of either βarr2 or 
miniGαq, the ‘intrinsic relative activity’ (RAi) was calculated for each compound in each 
bioassay.[18, 26] This value defines the ratio of Emax/EC50 of the tested compound to the 









𝐸𝐶50, LSD  ×  𝐸max,𝑖
𝐸max,LSD × 𝐸𝐶50,𝑖
 
For each individual compound, the obtained RAi values per pathway were then combined into 
the bias factor, βi, using the following formula:[18, 26] 






This formula implies that the bias factor for the reference agonist LSD is equal to 0 (as further 
discussed in section 3.2). Compounds with a positive value for β have a greater relative 
tendency towards recruitment of βarr2, while compounds with a negative β tend to favor 
recruitment of miniGαq. The statistical significance of the difference of each β from 0 was 
determined via a Kruskal-Wallis analysis (the non-parametric alternative to one-way ANOVA), 
with post-hoc Dunn’s test in GraphPad Prism. Furthermore, bias plots were generated to 
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qualitatively assess the extent of ligand bias towards one pathway or the other. The normalized 
AUC values of the three independent experiments of the miniGαq bioassay were plotted against 
those obtained in the βarr2 assay. Curves were fit using the centered second order polynomial 
(quadratic) fitting, using GraphPad Prism software.[30] 
3. Results 
3.1 Determination of the optimal configuration of GPCR and miniGαq  
For the determination of biased agonism, a bioassay was developed to monitor the recruitment 
of the engineered miniGαq protein to the 5-HT2AR, highly similar to a previously reported βarr2 
bioassay.[22-25] Analogously with this latter assay, the NanoBiT® technology (Nanoluciferase 
Binary Technology) was employed, a technique specifically designed for the monitoring of 
protein-protein interactions. To this end, the nanoluciferase enzyme is split into two inactive 
parts, each of which is fused to one of the potentially interacting proteins, in this case the 
miniGαq protein and the 5-HT2AR. Upon agonist binding, miniGαq is recruited to the activated 
receptor, resulting in functional complementation of the enzyme, which can be picked up by a 
bioluminescent signal in the presence of the enzyme’s substrate.[31] The four possible 
combinations of receptor and effector constructs were generated, and tested for the optimal 
sensitivity, as visually depicted in Figure 2A. For each of those combinations, the activation 
profile of unstimulated cells was compared with that of cells stimulated with 1 µM of the 
psychedelic agonist LSD. As visualized in Figure 2A, the upper two combinations (5-HT2AR-
SmBiT with LgBiT-miniGαq and 5-HT2AR-LgBiT with SmBiT-miniGαq) both showed an 
increased signal upon stimulation with LSD. The latter combination was selected based on the 
increase in signal upon agonist stimulation. Furthermore, this option employs the same receptor 
construct (5-HT2AR-LgBiT) as that employed in a previously developed βarr2 bioassay,[22] 
thereby eliminating an extra source of variability that would be introduced when using different 
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constructs. In contrast with the successful setup of a HEK 293T system stably expressing 5-
HT2AR-LgBiT with SmBiT-βarr2 [32], repeated attempts to generate a similar stable system for 
5-HT2AR-LgBiT with SmBiT-miniGαq were unsuccessful, for unknown reasons. Hence, rather 
than using stable cell systems for the evaluation of biased agonism (as performed before for 
cannabinoid, opioid and adenosine receptors), we used transiently transfected cells here.[28, 
30, 33] 
3.2 LSD as a reference agonist 
Figure 2B demonstrates the verification of the concentration-dependence of our new platform. 
Assessing the potential occurrence of ligand bias for a given compound requires the 
measurement of both bioassays, and comparison of the results to a reference agonist to eliminate 
system bias and observational bias while also guaranteeing comparability of the experimental 
conditions.[19, 21] LSD is a well-characterized psychedelic compound that was previously 
used as the reference agonist in experiments assessing the activity of compounds at the 5-HT2AR 
[22, 32]. Figure 2C shows the concentration-response curves obtained using LSD in the 
bioassays used here. The Figure shows two indistinguishably overlapping curves, with largely 
overlapping confidence intervals of the EC50 values: 5.95 nM (with a 95 % confidence interval 
of 3.54 – 11.5 nM) for the βarr2 bioassay, and 5.70 nM (2.79 – 12.8 nM) for the newly 
developed miniGαq bioassay. Therefore, we implemented LSD as the reference agonist within 
this set of experiments.  
3.3 Analysis of twelve psychedelic substances with divergent structures  
We then employed the optimized miniGαq bioassay simultaneously with the previously 
developed βarr2 bioassay, in order to determine the potential biased agonism of a set of 
psychedelic NPS. In the initial approach, a structurally divergent set of compounds was chosen, 
comprising 3 tryptamines and 9 diversely substituted phenylalkylamine compounds. All 
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structures are shown in Figure 1. The EC50 (as a measure of the potency of that compound in 
that specific bioassay) and Emax (as a measure of efficacy) values were determined, and, together 
with the values obtained for the reference agonist LSD, this allowed for the calculation of the 
bias factor, β. A negative β value implies a preference of that compound towards the miniGαq 
bioassay, a positive value towards the βarr2 bioassay, and a value (close to) 0 implies a lack of 
preference towards either, relative to the reference agonist LSD for which β = 0. All values are 
given in Table 1, and the associated overlay curves, representing the concentration-response 
curves of the compounds in the respective bioassays, are shown in Figure 3. 
Upon implementation of a Kruskal-Wallis analysis with post hoc Dunn’s test, several 
compounds showing statistically significant differences in bias compared to LSD were 
identified: 25H-NBF (β value of 0.928, p = 0.0023), 25H-NBMD (β value of 0.733, p = 0.0222), 
25H-NBOH (β value of 0.750, p = 0.0130) and 25H-NBOMe (β value of 0.710, p = 0.0222). 
3.4 Analysis of eight structurally related analogues 
Following the identification of several compounds showing a bias statistically significantly 
different from LSD, a second panel of structurally related substances was assayed to verify 
whether there was a link between certain structural features and the observed (lack of) biased 
agonism. Furthermore, as Bromo-DragonFLY represented a peculiar case, with no statistically 
significant relative bias (β value of 0.033), despite clearly different activation profiles for the 
miniGαq and βarr2 bioassay (Figure 3), we also analyzed its structural analogue 2C-B-FLY, as 
well as the enantiopure R-Bromo-DragonFLY. The results of this series of experiments, more 
specifically the EC50 and Emax values per compound and per bioassay, and their respective bias 
factors, are shown in Table 2. The associated overlays of the concentration-response curves 




Serotonergic psychedelics are defined as substances exerting their pharmacological actions 
mainly through activation of the 5-HT2AR. On a cellular level, receptor activation by an agonist 
can lead to the recruitment of a trimeric G protein to the receptor. In the case of the 5-HT2AR, 
the receptor mainly interacts with the Gαq protein, resulting in activation of phospholipase C 
(PLC), accumulation of inositol phosphates (IP) and diacylglycerol, and the release of 
intracellular Ca2+. Other signaling events include phospholipase A (PLA) activity, with the 
associated arachidonic acid release, and Ca2+ mobilization through channels in the cell 
membrane. In addition to the canonical G protein-related signaling pathways, other proteins can 
interact with the activated GPCR, such as β-arrestin 2 (βarr2). This latter scaffolding protein 
can not only influence the internalization and desensitization of the receptor, but can also induce 
signaling events.[1, 3-6] It remains elusive which (combination) of these effects is responsible 
for the psychedelic actions of those compounds, and to what extent phenomena such as biased 
signaling, receptor dimerization and the binding of other receptors are involved in the 
mechanism of action of those substances.[4-6, 16] 
The 5-HT2AR was one of the first GPCRs for which functional selectivity was recognized.[17, 
34, 35] The best described phenomenon at this receptor is the selective activation of either the 
PLC or the PLA pathway. In this context, several agonists with preference towards either 
pathway have been identified, and along with high-throughput screening methods for bias, 
several models have been developed to predict signaling properties.[34, 36-40] Additionally, 
the potential agonist-directed preference towards either Gαq activation or Ca
2+ mobilization has 
been explored.[41] Furthermore, biased agonism has been proposed as the mechanism behind 
the psychedelic nature of some, but not all 5-HT2AR agonists, as differences in transcriptome 
patterns were uncovered between psychedelic and non-psychedelic substances, through the 
differential activation of the Gi/o protein and the Src pathway.[42, 43] Contrarily, potential 
preference of βarr recruitment as compared to activation of the G protein pathway has only 
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recently been explored.[35] To maximally allow comparison between recruitment of either Gαq 
or βarr2, we developed a bioassay monitoring the recruitment of an engineered miniGαq protein, 
in order to complement our previously described βarr2 recruitment assay.[22] The comparison 
of potency and efficacy data obtained in these two distinct, yet highly analogous recruitment 
bioassays, each monitoring separate upstream signaling events in the same cell line and through 
the same technique, enables the estimation of potentially biased agonism within the tested 
compounds.  
Following the selection of the optimal configuration of the 5-HT2AR and the engineered 
miniGαq protein in the NanoBiT
® system, enabling the most sensitive monitoring, and the 
verification of the concentration-dependence of this response, the newly developed bioassay 
was used simultaneously with the previously developed βarr2 bioassay for the assessment of 
biased agonism.[22] A prerequisite of this type of experiments is the use of a suitable reference 
agonist, thereby guaranteeing optimal comparability of the experiments and eliminating system 
and observational bias.[19, 21] Within the employed system, the well-described psychedelic 
compound LSD was found to show no preference towards either recruitment of miniGαq or 
βarr2, reflected by the practically overlapping curves of the two bioassays, and the highly 
similar EC50 values (as illustrated by the overlapping confidence intervals). The obtained EC50 
values were within the same range as those previously reported with βarr2 bioassays performed 
in either transiently transfected cells and cells stably expressing the bioassay components.[22, 
32] Therefore, LSD was selected as the reference agonist. In literature, LSD has been identified 
as both unbiased or biased, depending on which pathways were monitored in which receptor 
subtype. Agonist-directed signaling has been described for LSD at the 5-HT2CR, where PI 
hydrolysis, PKC translocation and Ca2+ were compared between LSD and serotonin.[44] From 
crystal structure data, the LSD-bound 5-HT2BR showed hallmarks of an apparently βarr-biased 
state. This was supported by comparing the outcome of a Tango (βarr2 recruitment) assay 
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versus that of a Ca2+ mobilization assay, applied at the 5-HT2BR.[45, 46] However, LSD 
appeared relatively unbiased at the 5-HT1BR, when comparing the outcomes of a Tango versus 
a cAMP inhibition assay.[46] Importantly, the comparative outcome of bioassays that monitor 
receptor activation at different levels of signaling may strongly be influenced by a ‘plateauing’ 
effect in bioassays that monitor more downstream effects, as recently elegantly demonstrated 
by Gillis and Gondin and colleagues for the mu opioid receptor.[47] This may yield a somewhat 
distorted view on biased agonism. As a consequence, at present it is not entirely clear to what 
extent LSD can effectively be considered as βarr-biased at the 5-HT2AR. A more detailed 
description of the available information on the βarr2 pathway for psychedelic substances is 
provided further in the discussion section. Irrespective of the discussion to what extent LSD is 
to be considered βarr-biased, it may serve as a reference psychedelic, to which (the bias of) 
other psychedelics can be compared. Furthermore, several signaling properties at the 5-HT2AR 
have been comparatively explored for LSD: Gαq activation versus Ca
2+ mobilization, PLC 
versus PLA activation, and the induction of distinct transcriptome fingerprints.[37, 41-43] The 
comparison of those results to ours is not straightforward, as different comparator molecules 
and signaling pathways were used. From the above, it is clear that statements on ligand bias 
should always include referral to the utilized reference agonist(s), the assessed pathways and 
cell types. Although we employed bioassays that are maximally similar, there are still some 
variables that may need to be taken into account for the interpretation of the results. E.g., the 
βarr2 and miniGαq fusion proteins with SmBiT may intrinsically have different turnover times 
and/or may differ in strength and/or duration in terms of coupling to the receptor. As more 
stable complexes may show higher apparent efficacies, this is an important consideration that 
should be kept in mind.[48] Moreover, results are not only influenced by the assay system per 
se, but also by the cellular context. As the βarr2 and miniGαq bioassays utilized here both 
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employ overexpressed assay components, one should be cautious when attempting to 
extrapolate these findings to native expression systems.[20] 
The highly analogous bioassays were used to analyze a first panel of structurally diverse 
psychedelic compounds, consisting of three tryptamines and nine phenylalkylamines. All 
substances were identified as agonists for both the recruitment of miniGαq and βarr2, covering 
a broad range of both potency (EC50) and efficacy (Emax) values, as can be derived from Table 
1. The Table also provides the calculated bias factors (β), with the respective p values obtained 
from the Kruskal-Wallis analysis. A visual representation of the β values is given in Figure 5. 
From this set of twelve compounds, four psychedelics were identified as statistically 
significantly biased towards the recruitment of βarr2, relative to the reference agonist LSD: 
25H-NBF (β value of 0.928, p = 0.0023), 25H-NBMD (β value of 0.733, p = 0.0222), 25H-
NBOH (β value of 0.750, p = 0.0130) and 25H-NBOMe (β value of 0.710, p = 0.0222). As this 
value is logarithmic, a β value of 1 is to be interpreted as a tenfold preference of the agonist 
towards the recruitment of βarr2, over miniGαq, relative to LSD. All calculated β values were 
positive, ranging from 0.009 for mescaline, which is essentially unbiased, to 0.928 for 25H-
NBF. The latter suggests that this ligand induces a receptor conformation preferentially 
resulting in recruitment of βarr2 over miniGαq. Within this subset of psychedelic substances, 
the highest bias factors can be linked to the N-benzyl substituted subgroup of 
phenylalkylamines. While four statistically significantly biased phenylalkylamines were 
identified, no statistically significantly biased tryptamines were discovered, despite relatively 
high bias factors (0.33 – 0.57).  
When looking closely into the results obtained with the second panel, containing selected 
structural analogues of the phenylalkylamines in the first test panel, several trends can be 
observed in Table 2 and Figures 4 and 5. Both the structurally related analogue 2C-B-FLY of 
Bromo-DragonFLY, and its enantiopure isomer R-Bromo-DragonFLY, show similar profiles, 
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with markedly higher efficacies for the miniGαq bioassay than for the βarr2 recruitment assay, 
and potencies within the same order of magnitude. In literature, it has been reported that the R-
enantiomer of Bromo-DragonFLY is mainly responsible for the activity of the racemic 
mixture.[49] In line with this, we found that the R-enantiomer is capable of inducing the 
recruitment of βarr2 and miniGαq. Analogously to 2C-H and DOH, 2C-I and DOI show no 
statistically significant preference towards either pathway compared to LSD, with overlapping 
curves for 2C-I and an increased Emax for the miniGαq over the βarr2 bioassay for DOI. Within 
the category of N-benzyl substituted psychedelics (-NBF, -NBMD, -NBOH and -NBOMe), the 
trend in bias factor reveals that, within both the group of 25I-substances and that of 25H-
substances, the -NBF has the highest bias factor, and the -NBOMe has the lowest, resulting in 
25I-NBF being statistically significantly biased towards the βarr2 recruitment assay compared 
to LSD. While for 25I-NBF, 25I-NBMD and 25I-NBOH, the βarr2 curves are higher and more 
leftward shifted than those of miniGαq, this is not the case for 25I-NBOMe, exemplifying how 
a relatively small difference in structure can influence the bias profile of a compound.[45, 50, 
51] Whether the tethering of the methoxy groups on the phenyl moiety of the phenethylamine 
core (as in (R)-Bromo-DragonFLY and 2C-B-FLY), or the substitution of that core with an 
ortho-substituted N-benzyl group is determinative for a certain bias or particular activation 
profiles, has to be confirmed with more structural analogues. Additionally, the recent 
elucidation of the agonist-bound structure of the 5-HT2AR with an engineered Gαq protein will 
presumably shed more light on the structural features required for activation of one pathway or 
the other.[52] Although Kim et al. did not specifically determine ligand bias, the agonist-bound 
5-HT2AR structure shows a differential binding mode of 25CN-NBOH as compared to LSD, 
which could potentially result in distinct signaling properties. Interestingly, a BRET analysis 
with βarr2 and an engineered Gαq protein revealed a higher efficacy for 25CN-NBOH in the 
βarr2 assay, when compared to serotonin as a reference.[52] 
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As seen in Figure 5 and Tables 1 and 2, all calculated bias factors (β) are (at least slightly) 
positive, indicating a stronger preference towards the recruitment of βarr2 over miniGαq, 
compared to the reference psychedelic substance LSD. Important to note is the fact that, within 
the test group, no “perfectly biased” substances were identified, only activating one of the two 
bioassays.[21] First described to interact with the 5-HT2AR over 20 years ago, the exact 
functions of βarr2 at this receptor still remain largely elusive.[53] On the one hand, 5-HT2AR 
structural data indicate psychedelic substances to show a preference towards agonist-induced 
receptor desensitization,[54] with LSD claimed to be biased towards βarr2 recruitment over 
nonpsychedelic lysergamides (as discussed above).[45] Quantitative phosphoproteomics 
revealed different receptor phosphorylation patterns between psychedelic and non-psychedelic 
substances.[55] On the other hand, knockout mice and cell lines suggest divergent functions for 
this protein in the response to psychedelic and non-psychedelic ligands: the behavioral head 
twitch response is abrogated in βarr1/2 knockout mice in response to non-psychedelic 
substances, but not in response to DOI and N-methyltryptamines. In this context, it has been 
hypothesized that the recruitment of βarr may result in differential consequences for non-
psychedelic versus psychedelic substances.[56-59] Based on the calculated bias factors, the 
present data show a (slight) preference of the tested substances towards the recruitment of βarr2 
over that of miniGαq compared to LSD, without enabling a distinction between the function of 
βarr2 in signaling, desensitization, internalization, or a combination of these. Further 
complicating the interpretation of bias factors, is the lack of knowledge about which extent of 
bias is required to result in a differential response in vivo. It must therefore be noted that the 
statistically significant differences in bias factor cannot easily be translated to (relevant) 




Figures 3 and 5 reveal a remarkable observation for Bromo-DragonFLY, described in literature 
as extremely potent, showing a markedly different activation profile in the two bioassays: the 
compound reaches an Emax of 287 % in the miniGαq recruitment assay, whereas ‘only’ 122 % 
was reached in the βarr2 bioassay. In a previous study, which assessed βarr2 recruitment via a 
cell line stably expressing the constituents of this bioassay, this compound did not differ 
markedly from other tested compounds.[7, 32, 61] Our new findings provide a reasonable 
explanation for the discrepancy between our previous findings and those in literature, and 
invigorate the need for implementing different bioassays in the functional characterization of 
substances. Moreover, the case of Bromo-DragonFLY also nicely illustrates an inherent 
limitation of the commonly employed ‘relative activity’ approach. The overlay of the miniGαq 
and βarr2 concentration-response curves (shown in Figure 3) shows two clearly distinct curves, 
with largely different Emax values. On the other hand, the EC50 values obtained from the two 
bioassays are similar (3.32 nM in the miniGαq bioassay, versus 1.53 nM in the βarr2 bioassay), 
with overlapping 95 % confidence intervals. However, because the ratio between the EC50 
values of the two bioassays is the inverse of that of the Emax values, the bias factor equals out 
to 0.033, in stark contrast with the qualitative interpretation of the results. The important 
message that should be derived from this is that biased agonism cannot -and should not- be 
summarized by solely the calculated bias factor β. A more visual representation of the bias 
factor is the bias plot, as shown in Figure 6. The graph for Bromo-DragonFLY shows a curve 
which is bent towards the axis on which the percentage of miniGαq activation is placed. While 
not giving a quantitative value, the concomitant use of this approach can help to prevent 
overlooking exceptional cases, such as this compound.[18, 19, 21, 26] 
Figure 6 therefore shows the individual bias plots of each of the psychedelics included in the 
test panel. Roughly three types of plots can be observed: (i) the compounds showing a visually 
clear preference towards the recruitment of miniGαq ((R)-Bromo-DragonFLY, 2C-B-FLY and 
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mescaline); (ii) the compounds showing a qualitative preference towards the recruitment of 
βarr2 (25H/I-NBF, 25H/I-NBMD, 25H/I-NBOH, 25H/I-NBOMe and N-Me-2C-H); and (iii) 
the more ambiguous compounds, of which the curve starts at one side of that of the reference 
agonist, crosses the curve of the reference agonist and stops at the other side, or where the curve 
coincides with that of the reference agonist. Given the positive β factors calculated for all tested 
psychedelics, indicating a (slight) relative preference towards the recruitment of βarr2, the 
occurrence of this first group is remarkable, and emphasizes the necessity of also including a 
qualitative assessment of the potentially biased agonism, as outlined above. Importantly, for all 
substances for which the bias factor indicated a statistically significant relative bias towards the 
recruitment of βarr2, the bias plot supports this finding. 
Another qualitative method to visually estimate the occurrence of biased agonism between two 
bioassays, is the depiction of the Emax values of each of the tested substances in each of the 
assays, and evaluation of the change in ranking order. Similarly to the bias plot, this 
representation takes into account the efficacies of the agonists, without making a priori 
assumptions on the data, as was the case for the quantitative approach, where a Hill slope of 1 
in the nonlinear regression analysis is assumed.[21] This ‘change in ranking’ approach was 
applied on the obtained data, and the results are shown in Figure 7, allowing for the rapid 
identification of qualitatively biased substances. In Figure 7, these substances can be recognized 
via lines crossing each other, as an indication of a different relative ranking of the efficacies in 
the two bioassays, indicative of the occurrence of bias. Here, the Figure shows several crossing 
lines, and outspoken differences in both directions, as indicated by the color code (a red color 
for compounds that differ 9-10 ranks between the two assays, blue for 7-8 ranks difference, 
green for 5 or 6, and black for a difference of less than five places in the ranking order of the 
two assays). Employing similar bioassays with different receptor systems (cannabinoid receptor 
CB1 and the mu opioid receptor), the rank order of the relative efficacies remained largely the 
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same between the two bioassays, with less crossing lines in this graphical presentation.[30, 33] 
Here, however, we observed remarkable differences in ranking (substances shifting 9 or 10 
places) for 25H-NBF, 25I-NBF, 25I-NBMD and DIPT, with 25H-NBF and 25I-NBF coming 
forward as strongly biased towards βarr2 recruitment via all three assessment methods. Also 
for the other N-benzyl substituted phenethylamines, except for 25I-NBOMe, this graph shows 
rather large differences in ranking order between the two employed assays, consistent with their 
qualitative (and quantitative) preference towards the βarr2 assay (Figures 5 and 6). Despite the 
large difference in Emax values between the two employed bioassays, the ranking order of (R)-
Bromo-DragonFLY changes less. In short, even upon applying two maximally similar 
bioassays, the use of different methodologies to assess biased agonism yields a distinct view on 
what compounds can be classified as biased towards one pathway or the other, emphasizing the 
need of applying different methods to obtain an estimate of bias. 
In conclusion, we report on the successful development of a bioassay that monitors the 
recruitment of an engineered miniGαq protein to the activated 5-HT2AR. Following selection of 
the optimal configuration of this assay and the selection of LSD as a reference psychedelic 
substance, the optimized bioassay was used together with a previously developed analogous 
βarr2 bioassay for the assessment of biased agonism. The use of two highly analogous 
bioassays, monitoring recruitment upstream in the signaling pathway in a similar cell 
environment, and using the same technology, allows for an optimally comparative assessment. 
A panel of 3 tryptamines and 9 diversely substituted phenylalkylamines was subjected to 
analysis, and bias factors were calculated through the relative activity approach. Employing this 
method, several agonists statistically significantly biased relative to LSD, were identified within 
the group of phenylalkylamine psychedelics, more specifically the N-benzyl substituted 25H 
analogues 25H-NBF, 25H-NBMD, 25H-NBOH and 25H-NBOMe. Several trends were 
observed when testing a panel of 8 additional structural phenylalkylamine analogues. Although 
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no stringent conclusions could be drawn as to which structural features are responsible for the 
observed effects, N-benzylsubstituted substances and compounds in which the methoxy groups 
on the phenylalkyl moiety are tethered appear to be initiating particular signaling patterns. 
Overall, all bias factors were positive, indicative of a preference (either statistically significant 
or not) towards the recruitment of βarr2 over miniGαq relative to the reference compound, LSD. 
Comparison of the calculated bias factors with the qualitative assessment of the overlay curves 
and respective bias plots of the compound responses, shows apparent contrasts in conclusions 
that can be drawn, thereby hinting at the necessity of combining different approaches in 
conclusion making. 
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Figure 1: Structures of the compounds used for the determination of potential ligand bias: LSD, 
mescaline, phenylalkylamines and tryptamines, with the respective R-groups in the table next 
to the basic structure, and 2C-B-FLY and (R)-Bromo-DragonFLY, where the additional 
features of the latter compound are shown in grey: the methyl group and the aromatic core, 





Figure 2: (A) Selection of the optimal configuration of 5-HT2AR and miniGαq constructs in the 
NanoBiT® system. Activation profiles of each of the four possible combinations are shown, 
with black lines representing the solvent controls (‘Blank’) and red curves the agonist-
stimulated cells (‘1 µM LSD’). Triplicates of one representative experiment are shown, and the 
selected combination is emphasized in a red frame. RLU: Relative Light Units (B) Corrected 
activation profiles obtained by testing different concentrations of LSD in the miniGαq bioassay. 
Concentration-dependence of the monitored signals can be observed. (C) Overlay of the 




Figure 3: Overlay figures of the obtained concentration-response curves of each compound, in both of the employed bioassays. The blue dots 2 
represent the curves obtained with the β-arrestin 2 bioassay, the beige squares represent those obtained with the miniGαq bioassay. Note the different 3 
y-axis-scale used for Bromo-DragonFLY. Each data point represents the mean of three independent experiments, each performed in duplicate ± 4 




Figure 4: Overlay figures of the obtained concentration-response curves of the additional 2 
compounds, in both of the employed bioassays. The blue dots represent the curves obtained 3 
with the β-arrestin 2 bioassay, the beige squares represent those obtained with the miniGαq 4 
bioassay. Note the different y-axis-scale used for R-Bromo-DragonFLY. Each data point 5 
represents the mean of three independent experiments, each performed in duplicate ± SEM 6 




Figure 5: Visual representation of the calculated bias factors (β) for each of the tested 2 
compounds, calculated from three independent experiments. The β of reference agonist LSD is 3 
0, a positive value implies a preference towards βarr2 recruitment and a negative value towards 4 
miniGαq recruitment. Black circles represent substances included in the first tested group, grey 5 
triangles their respective structural analogues from the second test panel, both ± SEM (standard 6 
error of the mean). *: P < 0.05; **: P < 0.01.7 
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  1 
Figure 6: Individual bias plots of each of the substances assessed in the two bioassays, with the same subdivision as used in Figure 5. Each point 2 
represents the effect of one concentration of an agonist, visualizing the respective responses in each of the bioassays, where the x-axis shows the 3 
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percentage activation of the β-arrestin 2 bioassay and the y-axis that of the miniGαq bioassay. The black line visualizes reference agonist LSD, the 1 




Figure 7: Visual representation of the qualitative comparison of the efficacies of each of the 
individual test substances in the two bioassays. The substances from the original panel are 
depicted by full lines, those of the second panel by dashed lines. Differences in ranking order 
of the Emax values between the two bioassays are indicative of a qualitative preference towards 
either, and the colors visualize this difference: red stands for a difference of 9-10 ranks between 





Table 1: Overview of the obtained potency (EC50) and efficacy (Emax) parameters in both of the 
employed bioassays. These values, together with those of the reference agonist LSD, allowed 
for the calculation of the bias factor β, indicating a preference towards the βarr2 bioassay 
(positive value) or the miniGαq bioassay (negative value). The bias factors that are statistically 
significantly different from 0 (with a P value <0.05) are marked in bold. Emax values are 





Compound EC50 (nM) (CI) Emax (%) (CI) EC50 (nM) (CI) Emax (%) (CI) β P 
LSD 5.95 (3.54 - 11.5) 100 (91.3 - 109) 5.70 (2.79 - 12.8) 100 (88.6 - 111) 0 N.A. 
Mescaline  2372 (1574 - 3594) 74.3 (68.3 - 88.8) 3906 (2828 - 5357) 116 (109 - 125) 0.009 > 0.99 
Bromo-
dragonFLY 
1.53 (1.11 - 2.11) 122 (115 - 128) 3.32 (2.10 - 5.17) 287 (267 - 308) 0.033 > 0.99 
2C-H 1220 (865 - 1711) 73.7 (69.1 - 78.5) 1992 (1304 - 3062) 74 (68.1 - 80.3) 0.235 > 0.99 
N-Me-2C-H 2773 (1704 - 4510) 54.4 (49.1 - 60.3) 2249 (1026 - 5037) 28.2 (24.2 - 33.0) 0.194 > 0.99 
DOH  1132 (787 - 1624) 103 (96.2 - 110) 2793 (1773 - 4457) 146 (133 - 160) 0.334 > 0.99 
25H-NBF 190 (130 - 277) 107 (99.9 - 114) 911 (593 - 1369) 67.1 (61.4 - 73.1) 0.928 0.0023 
25H-NBMD 68 (46.1 - 98.0) 124 (116 - 133) 261 (140 - 490) 90.5 (79.5 - 103) 0.733 0.022 
25H-NBOH 6.50 (4.19 - 9.76) 143 (135 - 152) 22.1 (15.5 - 31.7) 118 (112 - 125) 0.750 0.013 
25H-NBOMe 5.91 (3.79 - 8.91) 153 (144 - 163) 19.3 (13.5 - 27.8) 146 (138 - 154) 0.710 0.022 
DMT  114 (82.8 - 155) 74 (70.2 - 78) 328 (201 - 530) 68.3 (62.8 - 74.1) 0.516 0.24 
DPT  181 (124 - 266) 95.1 (89.3 - 101) 1051 (686 - 1596) 144 (132 - 157) 0.570 0.075 







Table 2: Overview of the obtained potency (EC50) and efficacy (Emax) parameters in both the 
employed bioassays. These values, together with those of the reference agonist LSD, allowed 
for the calculation of the bias factor β, indicating a preference towards the βarr2 bioassay 
(positive value) or the miniGαq bioassay (negative value). The bias factors that are statistically 
significantly different from 0 (with a P value <0.05) are marked in bold. Emax values are 





Compound EC50 (nM) (CI) Emax (%) (CI) EC50 (nM) (CI) Emax (%) (CI) β P 
LSD 5.95 (3.54 - 11.5) 100 (91.3 - 109) 5.70 (2.79 - 12.8) 99.8 (88.6 - 111) 0 N.A. 
2C-B-FLY 8.07 (6.12 - 10.5) 80.3 (77.0 - 83.6) 19.4 (14.1 - 26.7) 134 (127 - 140) 0.180 > 0.99 
R-Bromo-
DragonFLY 
1.33 (1.02 - 1.74) 125 (120 - 130) 4.24 (3.04 - 5.80) 292 (278 - 307) 0.152 > 0.99 
2C-I 4.90 (3.29 - 7.13) 73.9 (69.9 - 77.9) 11.7 (8.95 - 15.3) 87.9 (84.2 - 91.6) 0.323 > 0.99 
DOI 3.39 (2.97 - 4.97) 104 (97.8 - 110) 10.2 (7.39 - 13.9) 157 (148 - 167) 0.313 > 0.99 
25I-NBF 7.70 (5.32 - 11.0) 120 (112 - 128) 20.6 (12.3 - 34.9) 71.9 (64.6 - 79.8) 0.671 0.026 
25I-NBMD 3.31 (2.40 - 4.56) 117 (111 - 123) 6.32 (3.46 - 11.0) 69.6 (63.2 - 76.2) 0.506 0.19 
25I-NBOH 1.22 (0.878 - 1.69) 135 (128 - 142) 2.15 (1.41 - 3.27) 111 (104 - 119) 0.341 > 0.99 
25I-NBOMe 1.27 (0.708 - 2.27) 141 (128 - 154) 2.23 (1.15 - 4.32) 160 (142 - 177) 0.202 > 0.99 
 
 
